专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

111. 发明授权

US07901900B2 Assay kit and antibody for human low molecular weight CD14 有权
标题翻译：用于人类低分子量CD14的测定试剂盒和抗体
公开(公告)号：US07901900B2
公开(公告)日：2011-03-08
申请号：US11987746
申请日：2007-12-04
申请人： Shoji Furusako , Kamon Shirakawa
发明人： Shoji Furusako , Kamon Shirakawa
IPC分类号： G01N33/53 , C07K16/18
CPC分类号： C07K14/70596 , C07K16/2896 , C07K2317/34 , G01N2800/26
摘要： The present invention provides an antibody prepared using a peptide as an antigen, the peptide having 8 to 30 amino acid residues selected from an amino acid sequence at positions 1 to 68 of human high-molecular-weight CD14, or an antibody that binds to a peptide having a specific amino acid sequence at a position among the positions 1 to 68. An assay kit for human low-molecular-weight CD14 using the antibody and an assay method of the present invention, preferably a sandwich method, are able to quantitatively or qualitatively determine human low-molecular-weight CD14 with high sensitivity and specificity in a simple manner, so that they are useful for the diagnosis of a patient suffering from sepsis.
摘要翻译：本发明提供使用肽作为抗原制备的抗体，所述肽具有选自人高分子量CD14的1至68位的氨基酸序列的8-30个氨基酸残基，或与在位置1至68之间的位置具有特定氨基酸序列的肽。使用抗体的人类低分子量CD14测定试剂盒和本发明的测定方法，优选夹心法可以定量地或以简单的方式定性测定人体低分子量CD14，具有高灵敏度和特异性，因此它们可用于诊断患有败血症的患者。

112. 发明申请

US20090092612A1 ANTI-PLATELET MEMBRANE GLYCOPROTEIN VI MONOCLONAL ANTIBODY 有权
公开(公告)号：US20090092612A1
公开(公告)日：2009-04-09
申请号：US11912757
申请日：2006-04-28
申请人： Hiroshi Takayama , Kamon Shirakawa , Shoji Furusako , Yoshitaka Hosaka , Tomokazu Matsusue , Katsuki Naitoh , Yumi Hotta , Tetsushi Kawahara , Motoyasu Honda
发明人： Hiroshi Takayama , Kamon Shirakawa , Shoji Furusako , Yoshitaka Hosaka , Tomokazu Matsusue , Katsuki Naitoh , Yumi Hotta , Tetsushi Kawahara , Motoyasu Honda
IPC分类号： A61K39/395 , C07K16/18 , C12N5/06 , C12N15/11 , C12P21/04
CPC分类号： C07K16/28 , A61K2039/505 , C07K16/2803 , C07K16/34 , C07K2317/24 , C07K2317/34 , C07K2317/54 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/75 , C07K2317/76 , C07K2317/92 , C07K2319/30
摘要： The present invention provides an antibody which has the following features, its active fragment, or a derivative thereof: a) It specifically binds to human platelet membrane glycoprotein VI (GPVI); b) The function to activate a platelet and/or the function to induce a thrombocytopenia in vivo are low; and c) It at least partially depletes GPVI on the platelet membrane by contacting with a platelet.

113. 发明授权

US07514240B2 EGR-EGFR complex 失效
标题翻译： EGF-EGFR复合物
公开(公告)号：US07514240B2
公开(公告)日：2009-04-07
申请号：US10503486
申请日：2002-09-12
申请人： Shigeyuki Yokoyama , Hideo Ogiso , Mikako Shirouzu , Osamu Nureki , Ryuichiro Ishitani , Kazuki Saito
发明人： Shigeyuki Yokoyama , Hideo Ogiso , Mikako Shirouzu , Osamu Nureki , Ryuichiro Ishitani , Kazuki Saito
IPC分类号： C12P1/00 , C12P21/04 , C07K14/00 , A61K38/27 , G06F19/00
CPC分类号： C07K16/2863 , A61K2039/505 , C07K14/485 , C07K14/71 , C07K16/22 , C07K2299/00 , C07K2317/32 , C07K2317/34
摘要： The present invention relates to a crystal of a complex of an epidermal growth factor (EGF) and an epidermal growth factor receptor (EGFR), a crystal of a complex of EGFR and a substance regulating EGFR activity, structure coordinates of these crystals, a method for screening for the substance regulating EGFR activity, a method for designing the substance regulating EGFR activity, a method for designing an EGFR variant or an EGF variant, a method for producing an EGFR variant or an EGF variant and an EGF variant or an EGFR variant obtainable by such method, a method for designing an epitope using the structure coordinates of the EGF-EGFR complex, a method for producing an anti-EGFR antibody or an anti-EGF antibody and an antibody obtainable by such method, a polypeptide or a salt thereof comprising a region that forms an EGFR dimerization site, and the like.
摘要翻译：本发明涉及表皮生长因子（EGF）和表皮生长因子受体（EGFR）的复合物的晶体，EGFR复合物的结晶和调节EGFR活性的物质，这些晶体的结构坐标，方法用于筛选调节EGFR活性的物质，设计调节EGFR活性的物质的方法，设计EGFR变体或EGF变体的方法，产生EGFR变体或EGF变体和EGF变体或EGFR变体的方法可以通过这种方法获得使用EGF-EGFR复合物的结构座标设计表位的方法，抗EGFR抗体或抗EGF抗体的制备方法和可通过这种方法获得的抗体，多肽或盐其包含形成EGFR二聚化位点的区域等。

114. 发明授权

US07465547B2 Methods for detecting human low molecular weight CD14 有权
标题翻译：检测人类低分子量CD14的方法
公开(公告)号：US07465547B2
公开(公告)日：2008-12-16
申请号：US10534257
申请日：2003-11-12
申请人： Shoji Furusako , Kamon Shirakawa
发明人： Shoji Furusako , Kamon Shirakawa
IPC分类号： C07K16/28 , C12P21/08 , G01N33/50 , G01N33/543 , G01N33/577
CPC分类号： C07K14/70596 , C07K16/2896 , C07K2317/34 , G01N2800/26
摘要： The present invention provides an antibody prepared using a peptide as an antigen, the peptide having 8 to 30 amino acid residues selected from an amino acid sequence at positions 1 to 68 of human high-molecular-weight CD14, or an antibody that binds to a peptide having a specific amino acid sequence at a position among the positions 1 to 68. An assay kit for human low-molecular-weight CD14 using the antibody and an assay method of the present invention, preferably a sandwich method, are able to quantitatively or qualitatively determine human low-molecular-weight CD14 with high sensitivity and specificity in a simple manner, so that they are useful for the diagnosis of a patient suffering from sepsis.
摘要翻译：本发明提供使用肽作为抗原制备的抗体，所述肽具有选自人高分子量CD14的1至68位的氨基酸序列的8-30个氨基酸残基，或与在位置1至68之间的位置具有特定氨基酸序列的肽。使用抗体的人类低分子量CD14测定试剂盒和本发明的测定方法，优选夹心法可以定量地或以简单的方式定性测定人体低分子量CD14，具有高灵敏度和特异性，因此它们可用于诊断患有败血症的患者。

115. 发明申请

US20070021504A1 Composition and/or method for preventing onset and/or recurrence of cardiovascular events 有权
标题翻译：用于预防心血管事件发作和/或复发的组合物和/或方法
公开(公告)号：US20070021504A1
公开(公告)日：2007-01-25
申请号：US11481956
申请日：2006-07-07
申请人： Mitsuhiro Yokoyama , Hideki Origasa , Masunori Matsuzaki , Yuji Matsuzawa , Yasushi Saito , Yuichi Ishikawa , Shinichi Oikawa , Jun Sasaki , Hitoshi Hishida , Hiroshige Itakura , Toru Kita , Akira Kitabatake , Noriaki Nakaya , Toshiie Sakata , Kazuyuki Shimada , Kunio Shirato
发明人： Mitsuhiro Yokoyama , Hideki Origasa , Masunori Matsuzaki , Yuji Matsuzawa , Yasushi Saito , Yuichi Ishikawa , Shinichi Oikawa , Jun Sasaki , Hitoshi Hishida , Hiroshige Itakura , Toru Kita , Akira Kitabatake , Noriaki Nakaya , Toshiie Sakata , Kazuyuki Shimada , Kunio Shirato
IPC分类号： A61K31/23
CPC分类号： A61K31/202 , A61K9/0053 , A61K9/48 , A61K31/232
摘要： Provided are composition and/or methods useful in preventing onset and/or recurrence of cardiovascular events, especially in patients who have escaped the unstable period after cardiovascular angioplasty or in hyperlipidemia patients who have been treated with HMG-CoA RI.
摘要翻译：提供用于预防心血管事件的发作和/或复发的组合物和/或方法，特别是在已经在心血管血管成形术后不稳定时期或在用HMG-CoA RI治疗的高脂血症患者中的患者中。

116. 发明授权

US07060791B2 Meltrins 失效
公开(公告)号：US07060791B2
公开(公告)日：2006-06-13
申请号：US09983531
申请日：2001-10-24
申请人： Atsuko Fujisawa , Toru Yamakawa , Kamon Shirakawa , Chitose Orii , Naoki Ogawa
发明人： Atsuko Fujisawa , Toru Yamakawa , Kamon Shirakawa , Chitose Orii , Naoki Ogawa
IPC分类号： A61K38/04
CPC分类号： C12N9/6489 , A61K38/00 , A61K2039/505 , C07K14/705 , C07K16/40 , C07K2317/76
摘要： The purpose of the present invention is to provide a novel protein involved in adhesion and fusion between myoblasts in the course of the formation of byotube. The present invention relates to Meltrins, which a membrane protein having fusion, adhesion and aggregation activity of cells, especially myoblast; and to polypeptides of their domains, DNAs encoding them, antisense RNA for these DNAs, various antibodies to Meltrins and the polypeptides of their domains, expression vectors containing these DNAs, and transformants by these vectors; as well as to the process for producing Meltrins and the polypeptides of their domains using those transformants and medical compositions comprising Meltrins or antagonist against them as an effective ingredient.

117. 发明申请

US20060014935A1 Fas ligand derived polypeptides 失效
标题翻译： Fas配体衍生多肽
公开(公告)号：US20060014935A1
公开(公告)日：2006-01-19
申请号：US10861934
申请日：2004-06-07
申请人： Shigekazu Nagata , Takashi Suda , Tomohiro Takahashi , Norio Nakamura
发明人： Shigekazu Nagata , Takashi Suda , Tomohiro Takahashi , Norio Nakamura
IPC分类号： C07K16/18
CPC分类号： C07K16/2875 , C07K14/70575 , C07K2319/00
摘要： This invention provides a novel polypeptide useful in the field of medicines, a novel DNA which encodes the novel polypeptide, a recombinant DNA molecule which contains the novel DNA, a transformant transformed with the novel DNA or the recombinant DNA molecule, a process for the purification of the novel polypeptide, a process for the production of the novel polypeptide, an antibody which recognize the novel polypeptide, an oligonucleotide complementary to the novel DNA and a novel screening method. Particularly this invention provides a novel polypeptide which is Fas ligand or a fragment thereof. This novel polypeptide can be used as an effective ingredient of a medicament for regulating the apoptosis in a living body. This novel polypeptide is obtained by identifying a DNA fragment which encodes the novel polpeptide, transforming a desired host with a recombinant DNA molecule which contains the DNA fragment and purifying the novel polypeptide produced by the resulting transformant. This novel polypeptide has a cytoplasmic domain, a transmembrane domain and extracellular domain and takes part in apoptosis.
摘要翻译：本发明提供了可用于药物领域的新型多肽，编码新型多肽的新型DNA，含有新DNA的重组DNA分子，用新型DNA或重组DNA分子转化的转化体，纯化方法的新型多肽的生产方法，识别新多肽的抗体，与新DNA互补的寡核苷酸和新的筛选方法。特别地，本发明提供了一种新的多肽，其是Fas配体或其片段。这种新型多肽可以用作调节活体细胞凋亡的药物的有效成分。通过鉴定编码新型多肽的DNA片段，通过含有该DNA片段的重组DNA分子转化所需宿主并纯化得到的转化体产生的新型多肽来获得该新型多肽。该新型多肽具有胞质结构域，跨膜结构域和细胞外结构域，并参与细胞凋亡。

118. 发明授权

US06951919B1 Fas ligand derivative 失效
标题翻译： Fas配体衍生物
公开(公告)号：US06951919B1
公开(公告)日：2005-10-04
申请号：US09508849
申请日：1998-09-17
申请人： Shigekazu Nagata , Masato Tanaka
发明人： Shigekazu Nagata , Masato Tanaka
IPC分类号： A61K38/00 , C07K14/525 , C07K14/705 , C12N15/12 , C07K1/00 , C07K2/00 , C07K14/00 , C07K17/00
CPC分类号： C07K14/70575 , A61K38/00 , C07K14/525
摘要： This invention provides a soluble Fas ligand which functions as a Fas antagonist or an apoptosis regulator, a novel Fas ligand derivative which has excellent apoptosis-inducing activity and cytotoxic activity, and a DNA encoding such peptide.
摘要翻译：本发明提供了作为Fas拮抗剂或凋亡调节剂起作用的可溶性Fas配体，具有优良细胞凋亡诱导活性和细胞毒活性的新型Fas配体衍生物和编码该肽的DNA。

119. 发明授权

US06897295B1 Antibodies and fragments thereof to Fas ligand and Fas ligand derived polypeptides 失效
标题翻译： Fas配体和Fas配体衍生多肽的抗体及其片段
公开(公告)号：US06897295B1
公开(公告)日：2005-05-24
申请号：US08683703
申请日：1996-07-16
申请人： Shigekazu Nagata , Takashi Suda , Tomohiro Takahashi , Norio Nakamura
发明人： Shigekazu Nagata , Takashi Suda , Tomohiro Takahashi , Norio Nakamura
IPC分类号： C07K14/705 , C07K16/00 , C07K2/00 , C07K16/28
CPC分类号： C07K16/2875 , C07K14/70575 , C07K2319/00
摘要： This invention provides a novel polypeptide useful in the field of medicines, a novel DNA which encodes the novel polypeptide, a recombinant DNA molecule which contains the novel DNA, a transformant transformed with the novel DNA or the recombinant DNA molecule, a process for the purification of the novel polypeptide, a process for the production of the novel polypeptide, an antibody which recognizes the novel polypeptide, an oligonucleotide complementary to the novel DNA and a novel screening method. Particularly this invention provides a novel polypeptide which is Fas ligand or a fragment thereof. This novel polypeptide can be used as an effective ingredient of a medicament for regulating the apoptosis in a living body. This novel polypeptide is obtained by identifying a DNA fragment which encodes the novel polypeptide, transforming a desired host with a recombinant DNA molecule which contains the DNA fragment and purifying the novel polypeptide produced by the resulting transformant. This novel polypeptide has a cytoplasmic domain, a transmembrane domain and extracellular domain and takes part in apoptosis.
摘要翻译：本发明提供了可用于药物领域的新型多肽，编码新型多肽的新型DNA，含有新DNA的重组DNA分子，用新型DNA或重组DNA分子转化的转化体，纯化方法的新多肽的生产方法，识别新多肽的抗体，与新DNA互补的寡核苷酸和新的筛选方法。特别地，本发明提供了一种新的多肽，其是Fas配体或其片段。这种新型多肽可以用作调节活体细胞凋亡的药物的有效成分。通过鉴定编码新多肽的DNA片段获得该新型多肽，用含有该DNA片段的重组DNA分子转化所需宿主，并纯化所得转化体产生的新型多肽。该新型多肽具有胞质结构域，跨膜结构域和细胞外结构域，并参与细胞凋亡。

120. 发明授权

US06858599B2 Tricyclic compound having spiro union 失效
标题翻译：具有螺旋结合的三环化合物
公开(公告)号：US06858599B2
公开(公告)日：2005-02-22
申请号：US10026606
申请日：2001-12-27
申请人： Hidemitsu Nishida , Fumihiko Saitoh , Kousuke Harada , Ikuya Shiromizu , Takafumi Mukaihira
发明人： Hidemitsu Nishida , Fumihiko Saitoh , Kousuke Harada , Ikuya Shiromizu , Takafumi Mukaihira
IPC分类号： C07D471/20 , C07D498/20 , A61K31/33 , A61K31/495 , C07D241/00 , C07D243/00 , C07D491/00
CPC分类号： C07D471/20 , C07D498/20 , G01N2333/96444 , G01N2500/00
摘要： This invention relates to tricyclic compounds having spiro union represented by the following formula (I) or its salt which is useful as a drug, and in particular, as an inhibitor for activated blood coagulation factor X, which can be administered orally and which exhibits strong anticoagulation action. The invention also relates to a pharmacophore which was derived from the compound and is useful in molecular designing of the FXa inhibitor.
摘要翻译：本发明涉及具有以下式（I）表示的螺旋结合物的三环化合物或其盐，其可用作药物，特别是作为活化凝血因子X的抑制剂，其可以口服给药，其表现出强烈的作用抗凝作用。本发明还涉及一种衍生自化合物并可用于FXa抑制剂分子设计的药效团。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式